Abstract
A total of 227 sera were analysed using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) to find novel serum biomarkers for lung cancer. The results showed that the 11.53, 11.70, 13.78, 13.90 and 14.07 k m/z peaks identified as native serum amyloid A (SAA), SAA with N-terminal Arg cleaved, native transthyretin (TTR) and its two variants significantly differentiated lung cancer sera from normal control sera (p <0.01). A 'biomarker pattern' combining SAA and TTR was tested to distinguish lung cancer patients from normal control individuals, and the diagnostic positive rate of lung cancer was improved to 91.6%.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma / blood
-
Adenocarcinoma / diagnosis
-
Adenocarcinoma of Lung
-
Adult
-
Aged
-
Biomarkers / blood
-
Carcinoma, Squamous Cell / blood
-
Carcinoma, Squamous Cell / diagnosis
-
Electrophoresis, Polyacrylamide Gel
-
Enzyme-Linked Immunosorbent Assay
-
Female
-
Humans
-
Immunoprecipitation
-
Lung Neoplasms / blood*
-
Lung Neoplasms / diagnosis*
-
Male
-
Middle Aged
-
Prealbumin / analysis
-
Prealbumin / immunology
-
Prealbumin / metabolism*
-
Protein Array Analysis
-
Sensitivity and Specificity
-
Serum Amyloid A Protein / analysis
-
Serum Amyloid A Protein / immunology
-
Serum Amyloid A Protein / metabolism*
-
Small Cell Lung Carcinoma / blood
-
Small Cell Lung Carcinoma / diagnosis
-
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Substances
-
Biomarkers
-
Prealbumin
-
Serum Amyloid A Protein